Dendritic  ||| S:0 E:10 ||| JJ
cells  ||| S:10 E:16 ||| NNS
pulsed  ||| S:16 E:23 ||| VBN
with  ||| S:23 E:28 ||| IN
tumor  ||| S:28 E:34 ||| NN
cells  ||| S:34 E:40 ||| NNS
killed  ||| S:40 E:47 ||| VBN
by  ||| S:47 E:50 ||| IN
high  ||| S:50 E:55 ||| JJ
hydrostatic  ||| S:55 E:67 ||| JJ
pressure  ||| S:67 E:76 ||| NN
induce  ||| S:76 E:83 ||| VB
strong  ||| S:83 E:90 ||| JJ
immune  ||| S:90 E:97 ||| JJ
responses  ||| S:97 E:107 ||| NNS
and  ||| S:107 E:111 ||| CC
display  ||| S:111 E:119 ||| VB
therapeutic  ||| S:119 E:131 ||| JJ
effects  ||| S:131 E:139 ||| NNS
both  ||| S:139 E:144 ||| CC
in  ||| S:144 E:147 ||| IN
murine  ||| S:147 E:154 ||| JJ
TC-1  ||| S:154 E:159 ||| NN
and  ||| S:159 E:163 ||| CC
TRAMP-C2  ||| S:163 E:172 ||| CD
tumors  ||| S:172 E:179 ||| NNS
when  ||| S:179 E:184 ||| WRB
combined  ||| S:184 E:193 ||| VBN
with  ||| S:193 E:198 ||| IN
docetaxel  ||| S:198 E:208 ||| JJ
chemotherapy  ||| S:208 E:221 ||| JJ
High  ||| S:221 E:226 ||| JJ
hydrostatic  ||| S:226 E:238 ||| JJ
pressure  ||| S:238 E:247 ||| NN
( ||| S:247 E:248 ||| -LRB-
HHP ||| S:248 E:251 ||| NNP
)  ||| S:251 E:253 ||| -RRB-
has  ||| S:253 E:257 ||| VBZ
been  ||| S:257 E:262 ||| VBN
shown  ||| S:262 E:268 ||| VBN
to  ||| S:268 E:271 ||| TO
induce  ||| S:271 E:278 ||| VB
immunogenic  ||| S:278 E:290 ||| JJ
cell  ||| S:290 E:295 ||| NN
death  ||| S:295 E:301 ||| NN
of  ||| S:301 E:304 ||| IN
cancer  ||| S:304 E:311 ||| NN
cells ||| S:311 E:316 ||| NNS
,  ||| S:316 E:318 ||| ,
facilitating  ||| S:318 E:331 ||| VBG
their  ||| S:331 E:337 ||| PRP$
uptake  ||| S:337 E:344 ||| NN
by  ||| S:344 E:347 ||| IN
dendritic  ||| S:347 E:357 ||| JJ
cells  ||| S:357 E:363 ||| NNS
( ||| S:363 E:364 ||| -LRB-
DC ||| S:364 E:366 ||| NNP
)  ||| S:366 E:368 ||| -RRB-
and  ||| S:368 E:372 ||| CC
subsequent  ||| S:372 E:383 ||| JJ
presentation  ||| S:383 E:396 ||| NN
of  ||| S:396 E:399 ||| IN
tumor  ||| S:399 E:405 ||| NN
antigens ||| S:405 E:413 ||| NN
.  ||| S:413 E:415 ||| .
In  ||| S:415 E:418 ||| IN
the  ||| S:418 E:422 ||| DT
present  ||| S:422 E:430 ||| JJ
study ||| S:430 E:435 ||| NN
,  ||| S:435 E:437 ||| ,
we  ||| S:437 E:440 ||| PRP
demonstrated  ||| S:440 E:453 ||| VBD
immunogenicity  ||| S:453 E:468 ||| VBN
of  ||| S:468 E:471 ||| IN
the  ||| S:471 E:475 ||| DT
HHP-treated  ||| S:475 E:487 ||| JJ
tumor  ||| S:487 E:493 ||| NN
cells  ||| S:493 E:499 ||| NNS
in  ||| S:499 E:502 ||| IN
mice ||| S:502 E:506 ||| NNS
.  ||| S:506 E:508 ||| .
HHP  ||| S:508 E:512 ||| NNP
was  ||| S:512 E:516 ||| VBD
able  ||| S:516 E:521 ||| JJ
to  ||| S:521 E:524 ||| TO
induce  ||| S:524 E:531 ||| VB
immunogenic  ||| S:531 E:543 ||| JJ
cell  ||| S:543 E:548 ||| NN
death  ||| S:548 E:554 ||| NN
of  ||| S:554 E:557 ||| IN
both  ||| S:557 E:562 ||| DT
TC-1  ||| S:562 E:567 ||| NNP
and  ||| S:567 E:571 ||| CC
TRAMP-C2  ||| S:571 E:580 ||| CD
tumor  ||| S:580 E:586 ||| NN
cells ||| S:586 E:591 ||| NNS
,  ||| S:591 E:593 ||| ,
representing  ||| S:593 E:606 ||| VBG
murine  ||| S:606 E:613 ||| JJ
models  ||| S:613 E:620 ||| NNS
for  ||| S:620 E:624 ||| IN
human  ||| S:624 E:630 ||| JJ
papilloma  ||| S:630 E:640 ||| JJ
virus-associated  ||| S:640 E:657 ||| JJ
tumors  ||| S:657 E:664 ||| NNS
and  ||| S:664 E:668 ||| CC
prostate  ||| S:668 E:677 ||| JJ
cancer ||| S:677 E:683 ||| NN
,  ||| S:683 E:685 ||| ,
respectively ||| S:685 E:697 ||| RB
.  ||| S:697 E:699 ||| .
HHP-treated  ||| S:699 E:711 ||| JJ
cells  ||| S:711 E:717 ||| NNS
induced  ||| S:717 E:725 ||| VBP
stronger  ||| S:725 E:734 ||| JJR
immune  ||| S:734 E:741 ||| JJ
responses  ||| S:741 E:751 ||| NNS
in  ||| S:751 E:754 ||| IN
mice  ||| S:754 E:759 ||| JJ
immunized  ||| S:759 E:769 ||| NN
with  ||| S:769 E:774 ||| IN
these  ||| S:774 E:780 ||| DT
tumor  ||| S:780 E:786 ||| NN
cells ||| S:786 E:791 ||| NNS
,  ||| S:791 E:793 ||| ,
documented  ||| S:793 E:804 ||| VBN
by  ||| S:804 E:807 ||| IN
higher  ||| S:807 E:814 ||| JJR
spleen  ||| S:814 E:821 ||| JJ
cell  ||| S:821 E:826 ||| NN
cytotoxicity  ||| S:826 E:839 ||| NNS
and  ||| S:839 E:843 ||| CC
increased  ||| S:843 E:853 ||| VBD
IFNγ  ||| S:853 E:858 ||| JJ
production  ||| S:858 E:869 ||| NN
as  ||| S:869 E:872 ||| IN
compared  ||| S:872 E:881 ||| VBN
to  ||| S:881 E:884 ||| TO
irradiated  ||| S:884 E:895 ||| VB
tumor  ||| S:895 E:901 ||| NN
cells ||| S:901 E:906 ||| NNS
,  ||| S:906 E:908 ||| ,
accompanied  ||| S:908 E:920 ||| VBN
by  ||| S:920 E:923 ||| IN
suppression  ||| S:923 E:935 ||| NN
of  ||| S:935 E:938 ||| IN
tumor  ||| S:938 E:944 ||| NN
growth  ||| S:944 E:951 ||| NN
in vivo  ||| S:951 E:959 ||| NN
in  ||| S:959 E:962 ||| IN
the  ||| S:962 E:966 ||| DT
case  ||| S:966 E:971 ||| NN
of  ||| S:971 E:974 ||| IN
TC-1  ||| S:974 E:979 ||| CD
tumors ||| S:979 E:985 ||| NNS
,  ||| S:985 E:987 ||| ,
but  ||| S:987 E:991 ||| CC
not  ||| S:991 E:995 ||| RB
TRAMP-C2  ||| S:995 E:1004 ||| CD
tumors ||| S:1004 E:1010 ||| NNS
.  ||| S:1010 E:1012 ||| .
Furthermore ||| S:1012 E:1023 ||| RB
,  ||| S:1023 E:1025 ||| ,
HHP-treated  ||| S:1025 E:1037 ||| JJ
cells  ||| S:1037 E:1043 ||| NNS
were  ||| S:1043 E:1048 ||| VBD
used  ||| S:1048 E:1053 ||| VBN
for  ||| S:1053 E:1057 ||| IN
DC-based  ||| S:1057 E:1066 ||| JJ
vaccine  ||| S:1066 E:1074 ||| NN
antigen  ||| S:1074 E:1082 ||| NN
pulsing ||| S:1082 E:1089 ||| NN
.  ||| S:1089 E:1091 ||| .
DC  ||| S:1091 E:1094 ||| NNP
co-cultured  ||| S:1094 E:1106 ||| NNP
with  ||| S:1106 E:1111 ||| IN
HHP-treated  ||| S:1111 E:1123 ||| JJ
tumor  ||| S:1123 E:1129 ||| NN
cells  ||| S:1129 E:1135 ||| NNS
and  ||| S:1135 E:1139 ||| CC
matured  ||| S:1139 E:1147 ||| VBN
by  ||| S:1147 E:1150 ||| IN
a  ||| S:1150 E:1152 ||| DT
TLR  ||| S:1152 E:1156 ||| NNP
9  ||| S:1156 E:1158 ||| CD
agonist  ||| S:1158 E:1166 ||| NNS
exhibited  ||| S:1166 E:1176 ||| VBP
higher  ||| S:1176 E:1183 ||| JJR
cell  ||| S:1183 E:1188 ||| NN
surface  ||| S:1188 E:1196 ||| NN
expression  ||| S:1196 E:1207 ||| NN
of  ||| S:1207 E:1210 ||| IN
maturation  ||| S:1210 E:1221 ||| JJ
markers  ||| S:1221 E:1229 ||| NN
and  ||| S:1229 E:1233 ||| CC
production  ||| S:1233 E:1244 ||| NN
of  ||| S:1244 E:1247 ||| IN
IL-12  ||| S:1247 E:1253 ||| NNP
and  ||| S:1253 E:1257 ||| CC
other  ||| S:1257 E:1263 ||| JJ
cytokines ||| S:1263 E:1272 ||| NN
,  ||| S:1272 E:1274 ||| ,
as  ||| S:1274 E:1277 ||| RB
compared  ||| S:1277 E:1286 ||| VBN
to  ||| S:1286 E:1289 ||| TO
the  ||| S:1289 E:1293 ||| DT
DC  ||| S:1293 E:1296 ||| NNP
pulsed  ||| S:1296 E:1303 ||| NN
with  ||| S:1303 E:1308 ||| IN
irradiated  ||| S:1308 E:1319 ||| JJ
tumor  ||| S:1319 E:1325 ||| NN
cells ||| S:1325 E:1330 ||| NNS
.  ||| S:1330 E:1332 ||| .
Immunization  ||| S:1332 E:1345 ||| NNP
with  ||| S:1345 E:1350 ||| IN
DC  ||| S:1350 E:1353 ||| NNP
cell-based  ||| S:1353 E:1364 ||| JJ
vaccines  ||| S:1364 E:1373 ||| JJ
pulsed  ||| S:1373 E:1380 ||| NN
with  ||| S:1380 E:1385 ||| IN
HHP-treated  ||| S:1385 E:1397 ||| JJ
tumor  ||| S:1397 E:1403 ||| NN
cells  ||| S:1403 E:1409 ||| NNS
induced  ||| S:1409 E:1417 ||| VBP
high  ||| S:1417 E:1422 ||| JJ
immune  ||| S:1422 E:1429 ||| JJ
responses ||| S:1429 E:1438 ||| NNS
,  ||| S:1438 E:1440 ||| ,
detected  ||| S:1440 E:1449 ||| VBN
by  ||| S:1449 E:1452 ||| IN
increased  ||| S:1452 E:1462 ||| JJ
spleen  ||| S:1462 E:1469 ||| JJ
cell  ||| S:1469 E:1474 ||| NN
cytotoxicity  ||| S:1474 E:1487 ||| NNS
and  ||| S:1487 E:1491 ||| CC
elevated  ||| S:1491 E:1500 ||| VBD
IFNγ  ||| S:1500 E:1505 ||| JJ
production ||| S:1505 E:1515 ||| NN
.  ||| S:1515 E:1517 ||| .
The  ||| S:1517 E:1521 ||| DT
DC-based  ||| S:1521 E:1530 ||| JJ
vaccine  ||| S:1530 E:1538 ||| NN
pulsed  ||| S:1538 E:1545 ||| NN
with  ||| S:1545 E:1550 ||| IN
HHP-treated  ||| S:1550 E:1562 ||| JJ
tumor  ||| S:1562 E:1568 ||| NN
cells  ||| S:1568 E:1574 ||| NNS
combined  ||| S:1574 E:1583 ||| VBN
with  ||| S:1583 E:1588 ||| IN
docetaxel  ||| S:1588 E:1598 ||| JJ
chemotherapy  ||| S:1598 E:1611 ||| NNS
significantly  ||| S:1611 E:1625 ||| RB
inhibited  ||| S:1625 E:1635 ||| JJ
growth  ||| S:1635 E:1642 ||| NN
of  ||| S:1642 E:1645 ||| IN
both  ||| S:1645 E:1650 ||| DT
TC-1  ||| S:1650 E:1655 ||| NNP
and  ||| S:1655 E:1659 ||| CC
TRAMP-C2  ||| S:1659 E:1668 ||| CD
tumors ||| S:1668 E:1674 ||| NNS
.  ||| S:1674 E:1676 ||| .
Our  ||| S:1676 E:1680 ||| PRP$
results  ||| S:1680 E:1688 ||| NNS
indicate  ||| S:1688 E:1697 ||| VBP
that  ||| S:1697 E:1702 ||| IN
DC-based  ||| S:1702 E:1711 ||| JJ
vaccines  ||| S:1711 E:1720 ||| JJ
pulsed  ||| S:1720 E:1727 ||| NN
with  ||| S:1727 E:1732 ||| IN
HHP-inactivated  ||| S:1732 E:1748 ||| JJ
tumor  ||| S:1748 E:1754 ||| NN
cells  ||| S:1754 E:1760 ||| NNS
can  ||| S:1760 E:1764 ||| MD
be  ||| S:1764 E:1767 ||| VB
a  ||| S:1767 E:1769 ||| DT
suitable  ||| S:1769 E:1778 ||| JJ
tool  ||| S:1778 E:1783 ||| NN
for  ||| S:1783 E:1787 ||| IN
chemoimmunotherapy ||| S:1787 E:1805 ||| NN
,  ||| S:1805 E:1807 ||| ,
particularly  ||| S:1807 E:1820 ||| RB
with  ||| S:1820 E:1825 ||| IN
regard  ||| S:1825 E:1832 ||| NN
to  ||| S:1832 E:1835 ||| TO
the  ||| S:1835 E:1839 ||| DT
findings  ||| S:1839 E:1848 ||| NNS
that  ||| S:1848 E:1853 ||| WDT
poorly  ||| S:1853 E:1860 ||| RB
immunogenic  ||| S:1860 E:1872 ||| CD
TRAMP-C2  ||| S:1872 E:1881 ||| CD
tumors  ||| S:1881 E:1888 ||| NNS
were  ||| S:1888 E:1893 ||| VBD
susceptible  ||| S:1893 E:1905 ||| JJ
to  ||| S:1905 E:1908 ||| TO
this  ||| S:1908 E:1913 ||| DT
treatment  ||| S:1913 E:1923 ||| NN
modality ||| S:1923 E:1931 ||| NN
.  ||| S:1931 E:1933 ||| .
